Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Biogen sees no need for big changes in wake of Alzheimer’s drug setback

  • Adam Feuerstein

By Adam Feuerstein April 24, 2019

Reprints
Biogen
Ruby Wallau for STAT

Biogen (BIIB) is going to buy back more of its own stock.

Any investor hoping for a more radical adjustment to the biotech’s strategic plan following the aducanumab failure — the Alzheimer’s drug setback triggered a $20 billion loss in market value — has to be disappointed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
The history of OxyContin, told through unsealed Purdue documents
The history of OxyContin, told through unsealed Purdue documents
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Under protest, FDA to convene advisory panel to review…
Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS
Why the world’s smallest wheelchairs are going unused
Why the world’s smallest wheelchairs are going unused
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…

Recommended Stories